Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
28 10 2023
Historique:
received: 06 02 2023
accepted: 17 10 2023
medline: 30 10 2023
pubmed: 29 10 2023
entrez: 29 10 2023
Statut: epublish

Résumé

The mortality impact of COVID-19 in Africa remains controversial because most countries lack vital registration. We analysed excess mortality in Kilifi Health and Demographic Surveillance System, Kenya, using 9 years of baseline data. SARS-CoV-2 seroprevalence studies suggest most adults here were infected before May 2022. During 5 waves of COVID-19 (April 2020-May 2022) an overall excess mortality of 4.8% (95% PI 1.2%, 9.4%) concealed a significant excess (11.6%, 95% PI 5.9%, 18.9%) among older adults ( ≥ 65 years) and a deficit among children aged 1-14 years (-7.7%, 95% PI -20.9%, 6.9%). The excess mortality rate for January 2020-December 2021, age-standardised to the Kenyan population, was 27.4/100,000 person-years (95% CI 23.2-31.6). In Coastal Kenya, excess mortality during the pandemic was substantially lower than in most high-income countries but the significant excess mortality in older adults emphasizes the value of achieving high vaccine coverage in this risk group.

Identifiants

pubmed: 37898630
doi: 10.1038/s41467-023-42615-6
pii: 10.1038/s41467-023-42615-6
pmc: PMC10613220
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6879

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Int J Infect Dis. 2023 Mar;128:61-68
pubmed: 36566776
Influenza Other Respir Viruses. 2023 Sep;17(9):e13173
pubmed: 37752065
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Nature. 2023 Jan;613(7942):130-137
pubmed: 36517599
Scand J Public Health Suppl. 2007 Aug;69:35-44
pubmed: 17676501
PLoS One. 2021 Jan 13;16(1):e0244474
pubmed: 33439880
Glob Health Action. 2014 Oct 29;7:25593
pubmed: 25377342
Lancet. 2020 May 2;395(10234):e81
pubmed: 32333839
Nat Commun. 2021 Jun 25;12(1):3966
pubmed: 34172732
PLoS Med. 2022 Nov 10;19(11):e1004107
pubmed: 36355774
Lancet Digit Health. 2021 Jun;3(6):e360-e370
pubmed: 34045002
PLOS Glob Public Health. 2022 Aug 18;2(8):e0000883
pubmed: 36962821
Int J Environ Res Public Health. 2021 Apr 12;18(8):
pubmed: 33921217
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
BMJ. 2022 Aug 2;378:e070695
pubmed: 35918098
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Lancet Glob Health. 2022 Aug;10(8):e1099-e1114
pubmed: 35659911
Bull World Health Organ. 2021 Jan 01;99(1):19-33F
pubmed: 33716331
Int J Public Health. 2021 Oct 05;66:1604249
pubmed: 34675760
Eur J Epidemiol. 2021 Jun;36(6):581-588
pubmed: 34322831
BMJ. 2021 May 19;373:n1137
pubmed: 34011491
Science. 2021 Nov 19;374(6570):989-994
pubmed: 34618602
PLoS One. 2020 Oct 9;15(10):e0240286
pubmed: 33035253
Soc Sci Med. 2016 Sep;164:59-73
pubmed: 27471131
AAS Open Res. 2020 Apr 17;3:4
pubmed: 32399515
Wellcome Open Res. 2023 Feb 17;6:327
pubmed: 37416502
Lancet Reg Health Am. 2021 Oct;2:None
pubmed: 34693394

Auteurs

M Otiende (M)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya. motiende@kemri-wellcome.org.

A Nyaguara (A)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

C Bottomley (C)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street London, London, WC1E 7HT, UK.

D Walumbe (D)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

G Mochamah (G)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

D Amadi (D)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

C Nyundo (C)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

E W Kagucia (EW)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

A O Etyang (AO)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

I M O Adetifa (IMO)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street London, London, WC1E 7HT, UK.

S P C Brand (SPC)

The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, CV4 7AL, UK.

E Maitha (E)

Department of Health, Kilifi County, Kilifi, Kenya.

E Chondo (E)

Department of Health, Kilifi County, Kilifi, Kenya.

E Nzomo (E)

Kilifi County Hospital, Kilifi, Kenya.

R Aman (R)

Ministry of Health, Government of Kenya; Afya House, Cathedral Road, Nairobi, Kenya.

M Mwangangi (M)

Ministry of Health, Government of Kenya; Afya House, Cathedral Road, Nairobi, Kenya.

P Amoth (P)

Ministry of Health, Government of Kenya; Afya House, Cathedral Road, Nairobi, Kenya.

K Kasera (K)

Ministry of Health, Government of Kenya; Afya House, Cathedral Road, Nairobi, Kenya.

W Ng'ang'a (W)

Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya.

E Barasa (E)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

B Tsofa (B)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

J Mwangangi (J)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

P Bejon (P)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.
Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7BN, UK.

A Agweyu (A)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.

T N Williams (TN)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.
Institute for Global Health Innovation, Imperial College, London, SW72AS, UK.

J A G Scott (JAG)

KEMRI-Wellcome Research Trust Programme, PO Box 230, Kilifi, 80108, Kenya.
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street London, London, WC1E 7HT, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH